Differences in the mutational landscape of triple-negative breast cancer in African Americans and Caucasians

Breast Cancer Research and Treatment

Volumn 161, Issue 3, 2017, Pages 491-499

  Ademuyiwa, Foluso O ^a   Tao, Yu ^a   Luo, Jingqin ^a   Weilbaecher, Katherine ^a   Ma, Cynthia X ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Genomics; Survival; Triple negative breast cancer

Indexed keywords

ADULT; AFRICAN AMERICAN; ARTICLE; CANCER GENETICS; CANCER PATIENT; CANCER SURVIVAL; CAUCASIAN; CLINICAL FEATURE; CLINICAL OUTCOME; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EXOME; GENE; GENE EXPRESSION PROFILING; HUMAN; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MLL3 GENE; MOLECULAR PATHOLOGY; MUTATIONAL ANALYSIS; PAM50 GENE; PIK3CA GENE; PREVALENCE; RACE DIFFERENCE; SOMATIC MUTATION; TRIPLE NEGATIVE BREAST CANCER; AGED; ALLELE; CANCER STAGING; FACTUAL DATABASE; FEMALE; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MUTATION; PROGNOSIS;

TUMOR MARKER;

ADULT; AFRICAN AMERICANS; AGED; ALLELES; BIOMARKERS, TUMOR; DATABASES, FACTUAL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROGNOSIS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 85001129855     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-016-4062-y     Document Type: Article

References (35)

1. Smigal C, Jemal A, Ward E, Cokkinides V, Smith R, Howe HL, Thun M (2006) Trends in breast cancer by race and ethnicity: update 2006. CA 56:168–183
2. Warner ET, Tamimi RM, Hughes ME, Ottesen RA, Wong YN, Edge SB, Theriault RL, Blayney DW, Niland JC, Winer EP, Weeks JC, Partridge AH (2015) Racial and ethnic differences in breast cancer survival: mediating effect of tumor characteristics and sociodemographic and treatment factors. J Clin Oncol 33:2254–2261. doi:10.1200/JCO.2014.57.1349
3. Chlebowski RT, Chen Z, Anderson GL, Rohan T, Aragaki A, Lane D, Dolan NC, Paskett ED, McTiernan A, Hubbell FA, Adams-Campbell LL, Prentice R (2005) Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst 97:439–448. doi:10.1093/jnci/dji064
4. Newman LA, Griffith KA, Jatoi I, Simon MS, Crowe JP, Colditz GA (2006) Meta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status. J Clin Oncol 24:1342–1349. doi:10.1200/JCO.2005.03.3472
5. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer 109:1721–1728. doi:10.1002/cncr.22618
6. Chen VW, Correa P, Kurman RJ, Wu XC, Eley JW, Austin D, Muss H, Hunter CP, Redmond C, Sobhan M et al (1994) Histological characteristics of breast carcinoma in blacks and whites. Cancer Epidemiol Biomark Prev 3:127–135
7. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492–2502. doi:10.1001/jama.295.21.2492
8. Gapstur SM, Dupuis J, Gann P, Collila S, Winchester DP (1996) Hormone receptor status of breast tumors in black, Hispanic, and non-Hispanic white women. An analysis of 13,239 cases. Cancer 77:1465–1471. doi:10.1002/(SICI)1097-0142(19960415)77:8<1465:AID-CNCR7>3.0.CO;2-B
9. Kroenke CH, Sweeney C, Kwan ML, Quesenberry CP, Weltzien EK, Habel LA, Castillo A, Bernard PS, Factor RE, Kushi LH, Caan BJ (2014) Race and breast cancer survival by intrinsic subtype based on PAM50 gene expression. Breast Cancer Res Treat 144:689–699. doi:10.1007/s10549-014-2899-5
10. Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, Flagg EW, O’Regan RM, Gabram SG, Eley JW (2009) Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat 113:357–370. doi:10.1007/s10549-008-9926-3
11. Ma H, Lu Y, Malone KE, Marchbanks PA, Deapen DM, Spirtas R, Burkman RT, Strom BL, McDonald JA, Folger SG, Simon MS, Sullivan-Halley J, Press MF, Bernstein L (2013) Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status. BMC Cancer 13:225. doi:10.1186/1471-2407-13-225
12. Pacheco JM, Gao F, Bumb C, Ellis MJ, Ma CX (2013) Racial differences in outcomes of triple-negative breast cancer. Breast Cancer Res Treat 138:281–289. doi:10.1007/s10549-012-2397-6
13. Perez CA, Zumsteg ZS, Gupta G, Morrow M, Arnold B, Patil SM, Traina TA, Robson ME, Wen YH, McCormick B, Powell SN, Ho AY (2013) Black race as a prognostic factor in triple-negative breast cancer patients treated with breast-conserving therapy: a large, single-institution retrospective analysis. Breast Cancer Res Treat 139:497–506. doi:10.1007/s10549-013-2550-x
14. Sachdev JC, Ahmed S, Mirza MM, Farooq A, Kronish L, Jahanzeb M (2010) Does race affect outcomes in triple negative breast cancer? Breast Cancer 4:23–33
15. Tao L, Gomez SL, Keegan TH, Kurian AW, Clarke CA (2015) Breast cancer mortality in African-American and non-Hispanic white women by molecular subtype and stage at diagnosis: a population-based study. Cancer Epidemiol Biomark Prev 24:1039–1045. doi:10.1158/1055-9965.EPI-15-0243
16. Field LA, Love B, Deyarmin B, Hooke JA, Shriver CD, Ellsworth RE (2012) Identification of differentially expressed genes in breast tumors from African American compared with Caucasian women. Cancer 118:1334–1344. doi:10.1002/cncr.26405
17. Grunda JM, Steg AD, He Q, Steciuk MR, Byan-Parker S, Johnson MR, Grizzle WE (2012) Differential expression of breast cancer-associated genes between stage- and age-matched tumor specimens from African- and Caucasian-American Women diagnosed with breast cancer. BMC Res Notes 5:248. doi:10.1186/1756-0500-5-248
18. Cancer Genome Atlas N (2012) Comprehensive molecular portraits of human breast tumours. Nature 490:61–70. doi:10.1038/nature11412
19. Keenan T, Moy B, Mroz EA, Ross K, Niemierko A, Rocco JW, Isakoff S, Ellisen LW, Bardia A (2015) Comparison of the genomic landscape between primary breast cancer in African American versus white women and the association of racial differences with tumor recurrence. J Clin Oncol 33:3621–3627. doi:10.1200/JCO.2015.62.2126
20. Dawood S, Broglio K, Kau SW, Green MC, Giordano SH, Meric-Bernstam F, Buchholz TA, Albarracin C, Yang WT, Hennessy BT, Hortobagyi GN, Gonzalez-Angulo AM (2009) Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes. J Clin Oncol 27:220–226. doi:10.1200/JCO.2008.17.9952
21. O’Brien KM, Cole SR, Tse CK, Perou CM, Carey LA, Foulkes WD, Dressler LG, Geradts J, Millikan RC (2010) Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res 16:6100–6110. doi:10.1158/1078-0432.CCR-10-1533
22. Sparano JA, Wang M, Zhao F, Stearns V, Martino S, Ligibel JA, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE (2012) Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial. J Natl Cancer Inst 104:406–414. doi:10.1093/jnci/djr543
23. Wright JL, Reis IM, Zhao W, Panoff JE, Takita C, Sujoy V, Gomez CR, Jorda M, Franceschi D, Hurley J (2012) Racial disparity in estrogen receptor positive breast cancer patients receiving trimodality therapy. Breast 21:276–283. doi:10.1016/j.breast.2011.11.003
24. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817–2826. doi:10.1056/NEJMoa041588
25. Ng CK, Pemberton HN, Reis-Filho JS (2012) Breast cancer intratumor genetic heterogeneity: causes and implications. Expert Rev Anticancer Ther 12:1021–1032. doi:10.1586/era.12.85
26. Duell EJ, Millikan RC, Pittman GS, Winkel S, Lunn RM, Tse CK, Eaton A, Mohrenweiser HW, Newman B, Bell DA (2001) Polymorphisms in the DNA repair gene XRCC1 and breast cancer. Cancer Epidemiol Biomark Prev 10:217–222
27. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383–391. doi:10.1038/86882
28. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, Smith LV, Labbok MH, Geradts J, Bensen JT, Jackson S, Nyante S, Livasy C, Carey L, Earp HS, Perou CM (2008) Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 109:123–139. doi:10.1007/s10549-007-9632-6
29. Bernards R, Weinberg RA (2002) A progression puzzle. Nature 418:823. doi:10.1038/418823a
30. Liu Y, Tobias DK, Sturgeon KM, Rosner B, Malik V, Cespedes E, Joshi AD, Eliassen AH, Colditz GA (2016) Physical activity from menarche to first pregnancy and risk of breast cancer. Int J Cancer 139:1223–1230. doi:10.1002/ijc.30167
31. Centers for Disease C, Prevention (2009) Differences in prevalence of obesity among black, white, and Hispanic adults—United States, 2006–2008. MMWR. Morbidity and mortality weekly report 58:740–744
32. Jackson CL, Wang NY, Yeh HC, Szklo M, Dray-Spira R, Brancati FL (2014) Body-mass index and mortality risk in U.S. blacks compared to whites. Obesity 22:842–851. doi:10.1002/oby.20471
33. Griggs JJ, Sorbero ME, Lyman GH (2005) Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med 165:1267–1273. doi:10.1001/archinte.165.11.1267
34. Lyman GH, Dale DC, Crawford J (2003) Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 21:4524–4531. doi:10.1200/JCO.2003.05.002
35. Shayne M, Crawford J, Dale DC, Culakova E, Lyman GH, Group ANCS (2006) Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat 100:255–262. doi:10.1007/s10549-006-9254-4